Moreover, patients with glioblastomas, endometrial carcinomas, or colorectal cancers with a high TMB are sensitive to immunotherapy with PD-1/PD-L1 inhibitors [22–24]. This evidence concerns the gene CD274 and endometrial carcinoma.